14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CGIX ranks #17386 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$1.68 (-8.20%)

Volume: 131k

Closed: Dec 03, 2021

Hollow Logo Score: -7.760

Cancer Genetics Stock Forecast

$1.68 (-8.20%)

Volume: 131k

Closed: Dec 03, 2021

Score Hollow Logo -7.760
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 12 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

High volatility in Cancer Genetics stock price on Friday which ended trading at $1.68
(Updated on Dec 03, 2021)

Sell candidate since 2021-11-11 Loss -34.38%

The Cancer Genetics stock price fell by -8.20% on the last day (Friday, 3rd Dec 2021) from $1.83 to $1.68. During the day the stock fluctuated 11.57% from a day low at $1.67 to a day high of $1.86. The price has fallen in 7 of the last 10 days and is down by -18.84% for this period. Volume has increased on the last day by 13 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 131 thousand shares were bought and sold for approximately $220.21 thousand.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($1.88) are considered to be a "second chance" to get out. According to the fan-theory $0.94 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Cancer Genetics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.90 and $2.23. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, November 04, 2021, and so far it has fallen -43.24%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Cancer Genetics gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.19 between high and low, or 11.57%. For the last week, the stock has had a daily average volatility of 7.20%.

Cancer Genetics is oversold on RSI14 (12). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Cancer Genetics stock A Buy?

Cancer Genetics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -7.760

Predicted Opening Price for Cancer Genetics of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$1.74 $1.68 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Volatility and Risk
Daily Average Volatility: 7.20 %
Overall Risk: Very High High Medium Low Very Low
7.20 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $1.83
Price: $1.68
No Support Found

CGIX Insider Trading Show all Trades


1 195.539

Last 100 transactions
Buy: 6 225 174 | Sell: 5 207 (Shares)
Date Action Amount Person Type
Jan 02, 2020 Buy 10 000 Miles Michael Glenn Stock Option (right to buy)
Jan 02, 2020 Buy 10 000 Brandt Ralf Stock Option (right to buy)
Jul 23, 2019 Buy 100 000 Harris Geoffrey E. Stock Option (right to buy)
Jul 23, 2019 Buy 100 000 Prendergast Franklyn G Stock Option (right to buy)
Jul 23, 2019 Buy 100 000 Chaganti Raju S.k. Stock Option (right to buy)
Show all Insider Trades

1 195.539

Last 100 transactions
Buy: 6 225 174 | Sell: 5 207 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.93 14.94 %
1.86 10.55 %
1.81 7.83 %
Current price: 1.68
Support 1.66 -0.96 %
1.62 -3.67 %
1.54 -8.07 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 2.07 23.21 %
2.05 22.02 %
1.83 8.93 %
Current price 1.68
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Cancer Genetics

Cancer Genetics Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biopharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE